Valvular heart disease in antiphospholipid syndrome

Current Rheumatology Reports

Volumn 15, Issue 4, 2013, Pages

  Zuily, Stéphane ^a,b,c,d   Huttin, Olivier ^a,e   Mohamed, Shirine ^a,d   Marie, Pierre Yves ^a,e   Selton Suty, Christine ^a,e   Wahl, Denis ^a,b,c,d  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d Institut Lorrain du C ur et des Vaisseaux Louis Mathieu   (France)

^e CHU NANCY BRABOIS   (France)

Author keywords

Anticoagulant; Antiphospholipid antibodies; Antiphospholipid syndrome; Antiplatelet therapy; Aortic valve; Bleeding; Cardiac surgery; Heart valve disease; Libman Sacks endocarditis; Mitral valve; Non bacterial endocarditis; Rheumatic disease; Stroke; Systemic lupus erythematosus; Thrombo embolic event; Thrombosis; Trans oesophageal echocardiography; Trans thoracic echocardiography; Valve dysfunction; Valve thickening

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CORTICOSTEROID; HEPARIN; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR MAGNETIC RESONANCE; CEREBROVASCULAR ACCIDENT; EARLY DIAGNOSIS; HEART VALVE REPLACEMENT; HUMAN; HYPERCOAGULABILITY; LIBMAN SACKS ENDOCARDITIS; MITRAL VALVE REGURGITATION; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PREVALENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE;

EID: 84874375187     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0320-8     Document Type: Article

References (55)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
2. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737-40.
3. Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012;64:1-10.
4. Cervera R, Tektonidou MG, Espinosa G, et al. Task force on catastrophic Antiphospholipid Syndrome (APS) and non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20:165-73.
5. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27.
6. Menard GE. Establishing the diagnosis of Libman-Sacks endocarditis in systemic lupus erythematosus. J Gen Intern Med. 2008;23:883-6.
7. Taguchi S, Hashimoto K, Sakamoto Y, Okuyama H, Ishii S. A case of mitral valve plasty for Libman-Sacks endocarditis mimicking a cardiac tumor. J Thorac Cardiovasc Surg. 2006;132:1465-7.
8. Ford SE, Lillicrap D, Brunet D, Ford P. Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic 'rheumatic type' valvular heart disease. Arch Pathol Lab Med. 1989;113:350-3.
9. Espinola-Zavaleta N, Amigo MC, Vargas-Barron J, et al. Two- and three-dimensional echocardiography in primary antiphospholipid syndrome: misdiagnosis as rheumatic valve disease. Lupus. 2001;10:511-3.
10. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924;33:701-37.
11. Eiken PW, Edwards WD, Tazelaar HD, McBane RD, Zehr KJ. Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985-2000. Mayo Clin Proc. 2001;76:1204-12.
12. Piette JC, Amoura Z, Papo T. Valvular heart disease and systemic lupus erythematosus. N Engl J Med. 1997;336:1324. author reply 1324-5.
13. Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006; 54:3918-25.
14. Morelli S, Bernardo ML, Viganego F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus. 2003;12:805-12.
15. Perez-Villa F, Font J, Azqueta M, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum. 2005;53:460-7.
16. Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005;95:1441-7.
17. Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology. 2007;108:331-7.
18. Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124:215-24.
19. Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke. 2005;36:592-6.
20. Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus. 2000;9:406-12.
21. Turiel M, Sarzi-Puttini P, Peretti R, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005;96:574-9.
22. Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol. 2004;31:2402-7.
23. Petri MA. Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. J Rheumatol. 2004;31:2329-30.
24. Ziporen L, Goldberg I, Arad M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996;5:196-205.
25. Blank M, Shani A, Goldberg I, et al. Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection. Thromb Res. 2004;114:589-92.
26. Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Revisiting Libman-Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol. 2009;36:126-30.
27. Lecompte T, Wahl D, Perret-Guillaume C, Hemker HC, Lacolley P, Regnault V. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007;92:714-5.
28. Liestol S, Sandset PM, Mowinckel MC, Wisloff F. Activated protein C resistance determined with a thrombin generationbased test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost. 2007;5:2204-10.
29. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579-87.
30. Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007;120:636-42.
31. Amoroso A, Cacciapaglia F, De Castro S, et al. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin Exp Rheumatol. 2006;24:287-94.
32. Balada E, Ordi-Ros J, Paredes F, Villarreal J, Mauri M, Vilardell- Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol. 2001;30:235-41.
33. Pardos-Gea J, Ordi-Ros J, Avegliano G, et al. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus. 2010;19:575-82.
34. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428-32.
35. Tektonidou MG, Kampolis CF, Moyssakis I, et al. Myocardial dysfunction and valvulopathy worsens with time in patients with antiphospholipid syndrome: a 10-year follow-up study. [Abstract 1738]. Presented at the American College of Rheumatology / ARHP Annual Meeting. Washington, USA; November 10-14, 2012.
36. Vinales KL, Gopalan RS, Lanza LA, Lester SJ, Chaliki HP. Unusual case of nonbacterial thrombotic endocarditis attributable to primary antiphospholipid syndrome. Circulation. 2010;122: e459-60.
37. Deo SV, Park SJ. Primary antiphospholipid antibody syndrome and Libmann-Sachs endocarditis. Mayo Clin Proc. 2011;86:929.
38. Shroff H, Benenstein R, Freedberg R, Mehl S, Saric M. Mitral valve Libman-Sacks endocarditis visualized by real time threedimensional transesophageal echocardiography. Echocardiogr. 2012;29:E100-1.
39. Roldan CA. Diagnostic value of transesophageal echocardiography in Libman-Sacks endocarditis. Minerva Cardioangiol. 2009;57:467-81.
40. Schneider C, Bahlmann E, Antz M, et al. Images in cardiovascular medicine. Unusual manifestation of Libman-Sacks endocarditis in systemic lupus erythematosus. Circulation. 2003;107:e202-4.
41. Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease is associated with nonfocal neuropsychiatric systemic lupus erythematosus. J Clin Rheumatol. 2006;12:3-10.
42. Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1490-3.
43. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum. 1997;27:27-35.
44. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12:518-23.
45. Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg. 2008;33:168-81.
46. Erdozain JG, Ruiz-Irastorza G, Segura MI, et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64:1256-60.
47. Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127:414-20.
48. Colli A, Mestres CA, Espinosa G, et al. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg. 2010;37:154-8.
49. Hegde VA, Vivas Y, Shah H, et al. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome-a caseseries. Heart Lung Circ. 2007;16:423-7.
50. Unger P, Plein D, Pradier O, LeClerc JL. Thrombosis of aortic valve homograft associated with lupus anticoagulant antibodies. Ann Thorac Surg. 2004;77:312-4.
51. Saito S, Ikeguchi H, Yamamoto H, Koike A, Yamaguchi K, Takeuchi E. Does antiphospholipid antibody syndrome affect bioprosthetic heart valve? midterm echocardiographic report. Jpn J Thorac Cardiovasc Surg. 2005;53:36-8.
52. Hogan WJ, McBane RD, Santrach PJ, et al. Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc. 2000;75:971-6.
53. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford). 2000;39:421-6.
54. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366:1705-15.
55. Maisano F, La Canna G, Colombo A, Alfieri O. The evolution from surgery to percutaneous mitral valve interventions: the role of the edge-to-edge technique. J Am Coll Cardiol. 2011;58:2174-82.